UCB S.A. is flexing the company’s M&A muscles once again with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a Covid-19 vaccine candidate under development by the two companies.
French drugmaker Sanofi SA expects to get approval for the potential COVID-19 vaccine in development with Britain’s GlaxoSmithKline Plc by the first half of 2021, faster than previously anticipated.
MADRID (Reuters) – The leaders of six European Union nations have called for building up EU stocks of critical medicines and equipment and other measures to boost the bloc’s long-term resilience to public health crises. The 27-nation EU and Britain have reported some 1.4 million cases of the new coronavirus, or about a fifth of […]
Sanofi SA said the company would sell its stake in Regeneron Pharmaceuticals Inc., but would not change their ongoing collaboration.
Vividion Therapeutics’ proteomics screening platform and small molecule library will be leveraged by the San Diego-based company and Roche to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.
There are more than 70 groups worldwide rushing to develop a vaccine against COVID-19, including Moderna, Johnson & Johnson, Pfizer and BioNTech, Novavax and many others. One of the groups that appears to be ahead of the race is not a commercial biopharma company: Oxford University’s Jenner Institute.
As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.
One of the key takeaways from BIO-Europe Spring 2020, which was held virtually March 23-27, was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.